Head to Head Review: Olympus (OTCMKTS:OCPNY) versus Hyperfine (NASDAQ:HYPR)

Hyperfine (NASDAQ:HYPR) and Olympus (OTCMKTS:OCPNY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Valuation & Earnings

This table compares Hyperfine and Olympus”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40 million	8.31	-$35.57 million	($0.38)	-2.35
Olympus	$7.74 billion	2.99	$1.03 billion	$0.82	21.95

Olympus has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hyperfine and Olympus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
Olympus	13.80%	24.30%	9.30%

Insider and Institutional Ownership

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 0.0% of Olympus shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Hyperfine has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Olympus has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Hyperfine and Olympus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	1	3	0	2.40
Olympus	0	0	1	0	3.00

Hyperfine currently has a consensus target price of $2.03, suggesting a potential upside of 127.49%. Given Hyperfine’s higher possible upside, equities analysts plainly believe Hyperfine is more favorable than Olympus.

Summary

Olympus beats Hyperfine on 8 of the 14 factors compared between the two stocks.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

About Olympus

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.